Type to search

Bioscience and pharmaceutical New Castle County News

AstraZeneca closes $2M precision med company buy

Katie Tabeling
Share

AstraZeneca headquarters in Wilmington | DBT FILE PHOTO

WILMINGTON AstraZeneca has recently completed a $2.4 billion deal for a California-based pharmaceutical company that gives the company a boost in next-generation cancer treatments.

The deal closed on June 5 and grants AstraZeneca an entry into precision medicine via Fusion Pharmaceuticals Inc. radioconjugates, or a drug that combines a radioactive isotope with a targeting agent like antibodies, peptides or small molecules   that seeks cancer cells. Fusion’s lead program is FPI-226, a small molecule targeting prostate cancers with a resistant strain.

FPI-226, which is now in AstraZeneca’s portfolio, is now in the second clinical trials.

Between 30 and 50% of patients with cancer today receive radiotherapy at some point during treatment, and the acquisition of Fusion furthers our ambition to transform this aspect of care with next-generation radioconjugates,” AstraZeneca Executive Vice President of Oncology R&D Susan Galbraith said.

“Together with Fusion, we have an opportunity to accelerate the development of FPI-2265 as a potential new treatment for prostate cancer and to harness their innovative actinium-based platform to develop radioconjugates as foundational regimens,” she added.

The deal also follows a series of deals signed by AstraZeneca, including a $1 billion buy last winter for cell therapy firm Gracell Biotechnologies. 

Under the terms of agreement, AstraZeneca has acquired all of Fusion’s shares at a price of $21 per share, and a contingent value of $3 per share,  if a regulatory milestone is met in 2029. In all, the deal is valued at $2.4 billion.

AstraZeneca’s oncology sales were $17.15 billion in 2023, or roughly one-third of its total revenue. The company will also use the Fusion acquisition to strengthen its foothold in Canada, joining its 76,000 employees worldwide. AstraZeneca has 1,600 employees in Delaware.

Get the free DBT email newsletter  

Follow the people, companies and issues that matter most to business in Delaware.

Tags:

You Might also Like

Leave a Comment

Your email address will not be published. Required fields are marked *

Premier Digital Partners

© 2024 Delaware Business Times